November 2nd 2023
Freshta Poupal, RN, and Frannie Bell, NP, share their experiences with teclistamab in clinical practice.
October 2nd 2023
Resistance training and walking can be beneficial for patients with multiple myeloma.
October 1st 2023
Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.
September 30th 2023
In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.
September 19th 2023
Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia.
FDA Approves Motixafortide Plus G-CSF To Mobilize Hematopoietic Stem Cells in Multiple Myeloma
The FDA has approved motixafortide in combination with filgrastim to mobilize hematopoietic stem cells in multiple myeloma transplantation, based on findings from the phase 3 GENESIS trial.
With New Bispecific Antibodies in Multiple Myeloma, Nurses Need To Know How to Manage CRS
Elizabeth Aronson, MSN, FNP-BCN, OCN, discusses how the recent approvals of elranatamab and talquetamab are changing the treatment landscape for patients with multiple myeloma.
Mezigdomide Plus Dexamethasone Generates Encouraging Responses in R/R Myeloma
Patients with heavily pretreated relapsed/refractory multiple myeloma, including those with lenalidomide and pomalidomide-refractory disease, showed encouraging responses with mezigdomide plus dexamethasone.
Black Patients With Multiple Myeloma May Require Additional Peripheral Neuropathy Monitoring When Receiving Bortezomib
Black patients with multiple myeloma may be at a higher-risk for bortezomib-induced peripheral neuropathy compared with non-Black patients.
FDA Grants Elranatamab Accelerated Approval for Relapsed or Refractory Multiple Myeloma
The FDA has granted accelerated approval to elranatamab-bcmm to treat adults with relapsed or refractory multiple myeloma who have already undergone 4 prior lines of treatment.
Oncology Drug Crash Course: Teclistamab-cqyv (Tecvayli)
Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.
Talquetamab Receives Accelerated Approval for Heavily Pretreated Multiple Myeloma
Talquetamab has received accelerated approval for patients with relapsed or refractory multiple myeloma.
Multiple Myeloma Treatment Evolution Expands Need for APP Education
Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.
Hematologic Oncology Undergoes Transformation With Drug Updates and Approvals
Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.
Prognostic Awareness Impacts QOL in Patients With Myeloma
Patients with myeloma who reported that their disease was incurable had lower quality of life. However, many patients may also have misconceptions about the curability of their disease.
FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
FDA Approves Melphalan Flufenamide Combo for Triple-Refractory Myeloma
The FDA approved melphalan flufenamide (Pepaxto; melflufen) plus dexamethasone for adults with triple-refractory multiple myeloma.
CAR T-Cell Therapy Is Promising in Myeloma
Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma
CAR T-cell therapy may change the treatment paradigm for relapsed/refractory myeloma.
Frontline Treatment Decisions Are Crucial in Myeloma
Although many patients will eventually relapse, the first remission is the deepest, according to one expert.
FDA Issues Clinical Hold on CAR-T Cell Trial for Patients With Myeloma
The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma, according to Cellectis, the manufacturer of the product.
Examining Distress Levels in Caregivers of Multiple Myeloma Patients
Caregivers of patients with multiple myeloma face similar challenges to those faced by the patients themselves.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512